Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

The healthcare leader posted adjusted earnings per share of $1.26 for the quarter, slightly above the consensus estimate of ...

International Business Machines said Thursday that it had joined forces with Moderna for a case study that evidenced quantum ...